The Relationship Between Brain Injury Biomarkers in Cerebrospinal Fluid and Blood of Patie
This study is a single-center, prospective, observational study. After successful cardiopulmonary resuscitation for patients with cardiac arrest, they will be transferred to the emergency intensive care unit for further standardized targeted temperature management. When evaluating that the patient meets the indications
| Condition(s) | Cardiac Arrest (CA), Brain Injuries, Acute |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | This study is a single-center, prospective, observational study. After successful cardiopulmonary resuscitation for patients with cardiac arrest, they will be transferred to the emergency intensive care unit for further standardized targeted temperature management. When evaluating that the patient meets the indications for lumbar puncture and there are no contraindications for lumbar puncture, lumbar puncture examinations will be completed immediately after return of spontaneous circulation (ROSC), at 24 hours of hypothermia, at 72 hours of hypothermia, and after rewarming. Routine cerebrospinal fluid examinations such as cerebrospinal fluid routine, cerebrospinal fluid biochemistry, and cerebrospinal fluid lactate will be sent for inspection. At the same time, 6 ml of cerebrospinal fluid |
| Who can participate | Inclusion Criteria: * Age ≥ 18 years old. * Still lack of directive movements after restoration of spontaneous circulation through cardiopulmonary resuscitation. * Advanced life support and targeted temperature management are carried out within 6 hours after return of spontaneous circulation (ROSC). Exclusion Criteria: * Patients with contraindications for lumbar puncture (severe cerebral edema indicated by brain imaging, disappearance of basal cisterns or occult intracranial mass lesions, receiving antiplatelet and anticoagulant therapy, and those with coagulation disorders). * Pregnant patients. * Patients with concomitant traumatic brain injury, stroke, cerebral hemorrhage and other diseases. * Patients whose families do not agree to be enrolled. |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Lead sponsor | Tang Ziren |
| Locations | Beijing, China |
| Start date | 2023-01-01 |
| NCT ID | NCT06624488 |
| Official listing | https://clinicaltrials.gov/study/NCT06624488 |